Why Does Everything Look Gray When You Feel Blue?
Philadelphia, PA, 20 July, 2010 - Regardless of culture, language, era, or individual artist, the arts consistently depict depression using darkness. Scientific findings now lend empirical support to this representation of depression that everything looks gray when you feel blue.
Researchers at the University of Freiburg in Germany showed previously that people with depression have difficulty detecting black-and-white contrast differences.
Publishing a new report in Biological Psychiatry, these scientists combined neuropsychiatric and ophthalmologic investigations to focus on the response of the retina to varying black-and-white contrasts. Specifically, they measured the pattern electroretinogram, which is like an electrocardiogram (ECG) of the retina of the eye, in patients with depression and healthy individuals.
They found dramatically lower retinal contrast gain in the depressed patients, regardless of whether or not they were receiving antidepressant medication. There was also a significant correlation between contrast gain and severity of depression, meaning those with the most severe symptoms of depression also had the lowest retinal responses. The electrophysiological signal of response was sufficiently consistent to distinguish most depressed patients from the healthy subjects.
“These data highlight the profound ways that depression alters one’s experience of the world,” commented Dr. John Krystal, Editor of Biological Psychiatry. “The poet William Cowper said that ‘variety’s the very spice of life’, yet when people are depressed, they are less able to perceive contrasts in the visual world. This loss would seem to make the world a less pleasurable place.”
Lead author Dr. Ludger Tebartz van Elst noted that although these findings are strong, they still need to be replicated in further studies. However, “this method could turn out to be a valuable tool to objectively measure the subjective state of depression, having far-reaching implications for research as well as clinical diagnosis of and therapy for depression.”
# # #
Notes to Editors:
The article is “Seeing Gray When Feeling Blue? Depression Can Be Measured in the Eye of the Diseased” by Emanuel Bubl, Elena Kern, Dieter Ebert, Michael Bach, and Ludger Tebartz van Elst. The authors are affiliated with the Department of Psychiatry and Psychotherapy, Albert-Ludwigs-University of Freiburg, Freiburg, Germany. Bach is also with Universitäts-Augenklinik Freiburg, Sektion Funktionelle Sehforschung, Freiburg, Germany. The article appears in Biological Psychiatry, Volume 68, Issue 2 (July 15, 2010), published by Elsevier.
The authors’ disclosures of financial and conflicts of interests are available in the article.
John H. Krystal, M.D. is Chairman of the Department of Psychiatry at the Yale University School of Medicine and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here. Full text of the article mentioned above is available upon request. Contact Maureen Hunter at firstname.lastname@example.org to obtain a copy or to schedule an interview.
About Biological Psychiatry
This international rapid-publication journal is the official journal of the Society of Biological Psychiatry. It covers a broad range of topics in psychiatric neuroscience and therapeutics. Both basic and clinical contributions are encouraged from all disciplines and research areas relevant to the pathophysiology and treatment of major neuropsychiatric disorders. Full-length and Brief Reports of novel results, Commentaries, Case Studies of unusual significance, and Correspondence and Comments judged to be of high impact to the field are published, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Concise Reviews and Editorials that focus on topics of current research and interest are also published rapidly.
Biological Psychiatry (www.sobp.org/journal) is ranked 4th out of the 101 Psychiatry titles and 14th out of 219 Neurosciences titles on the 2008 ISI Journal Citations Reports® published by Thomson Scientific.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai’s Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.
Strategic Marketing Manager - Elsevier
Tel: +1 215-239-3674